1 friday, april 19 Biochemistry and Molecular Biology asbmb graduate and postdoctoral travel award keynote lecture special Session

M. Balda. University Col. London.

10:45  Intranasal drugs, biopharmaceuticals and stem cells 

bypass the blood-brain barrier to treat Alzheimer’s, 

Parkinson’s, stroke, brain tumors, PTSD, TBI and 

other CNS disorders. 

W.H. Frey II. Regions Hosp., St. 

Paul.

11:20 

Gene delivery across the blood brain barrier for treating 

neurological disorders. 

B. K. Kaspar. Nationwide 

Children’s Hosp., Columbus.

146.  JULIUS AXELROD AWARD LECTURE

Lecture

s

un

. 2:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 107aB

The Julius Axelrod Award in Pharmacology, presented 

annually for significant contributions to understanding the 

biochemical mechanisms underlying the pharmacological actions 

of drugs and for contributions to mentoring other pharmacologists, 

was established to honor the memory of the eminent American 

pharmacologist who shaped the fields of neuroscience, drug 

metabolism and biochemistry and who served as a mentor for 

numerous eminent pharmacologists around the world. Dr. Gavril 

Pasternak was selected as the 2012 Award winner for his major 

contributions into the differential roles of opiate receptor subtypes 

in relieving pain with diminished side effects.

2:00 Introduction. 

K. Neve. VA Med. Ctr., Portland.

2:05 

No pain, big gain: truncated mu opioid receptor splice 

variants as drug targets. 

G. Pasternak. Mem. Sloan-

Kettering Cancer Ctr.

147.  JULIUS AXELROD SYMPOSIUM: EXPANDING 

THE REPERTOIRE OF G-PROTEIN COUPLED 

OPIOID RECEPTOR TARGETS

Symposium

(Supported by the John V. Croker Fund)

s

un

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 107aB

C

haired

: G.W. p

asternaK

3:00 

Alternative pre-RNA splicing of the mu opioid receptor 

gene: insight into complex mu opioid actions. 

Y-X. 

Pan. Mem. Sloan-Kettering Cancer Ctr.

3:35 

Opioid receptor heteromers: new pharmacology and 

new therapeutic possibilities. 

L. A. Devi. Mount Sinai 

Sch. of Med.

4:10 

Biased agonism and trafficking: discriminating opioid 

drug actions by receptor endocytosis. 

M. Von Zastrow. 

UCSF.

4:45 

The genetics of opioid analgesia. 

J. S. Mogil. McGill 

Univ.

5:20 Discussion.

148.  TRANSLATING PHARMACOLOGY INTO 

CAREER CHOICES IN THE PHARMACEUTICAL 

AND BIOTECHNOLOGY INDUSTRY

Symposium

(Sponsored by: The Divisions for Pharmacology 

Education; Drug Discovery and Development; and 

Integrative Systems, Translational and Clinical 

Pharmacology)

s

un

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 106

C

haired

: J. C

larK

Career Development

3:00 

Educational initiatives in pharmacology for a career 

in the pharmaceutical or biotechnology industry. 

 

J. Barrett. Drexel Univ. Col. of Med.

PHARMACOLOGY SUNDAY

43

S

U

N

3:30 

Pharmacology in target identification and validation. 

 

P. Hutson. Shire Pharmaceut.

4:00 

Pharmacogenetics in drug discovery and development. 

D. Stone. Merck Res. Labs.

4:30 

Pharmacoepidemiology: studying drugs in populations. 

S. Hennessy. Perelman Sch. of Med., Univ. of 

Pennsylvania.

5:00 

Clinical pharmacology and the development of drugs.  

D. Abernethy. FDA, Annapolis.

149.  EPIGENETIC CONTROL OF DRUG 

METABOLISM AND TRANSPORT

Symposium

(Sponsored by: The Divisions for Drug Metabolism; 

Drug Discovery and Development; Integrative Systems, 

Translational and Clinical Pharmacology; Molecular 

Pharmacology; and Toxicology)

s

un

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 107C

C

haired

: a. y

u

 

anD

 y. o

saWa

3:00 

Overview of genetic and epigenetic mechanisms 

underlying variable drug metabolism and drug 

response. 

M. Ingelman-Sundberg. Karolinska Inst.

3:30 

Chromatin modification in control of drug metabolism 

during liver development. 

X. Zhong. Univ. of Kansas 

Med. Ctr.

4:00 

Role of epigenetic mechanisms in differential regulation 

of the dioxin-inducible CYP1A1 and CYP1B1 genes. 

O. Hankinson. UCLA David Geffen Sch. of Med.

4:30 

Noncoding RNAs in post-transcriptional control of drug 

metabolism and transport. 

A. Yu. Univ. at Buffalo, 

SUNY.

5:00 

Long noncoding RNAs and transcription of cytochrome 

P450s in mouse liver during maturation. 

L. Peng, A. 

Paulson, H. Li, X. He, H. Lu, C.D. Klaassen, L. Li 

and X-b. Zhong. Univ. of Connecticut, Univ. of Kansas 

Med. Ctr., Stowers Inst. for Med. Res., MO and SUNY 

Upstate Med. Univ. 

(1102.7)

5:20 Discussion.

150.  INNATE IMMUNITY AND CARDIOVASCULAR 

DISEASE: UNFOLDING THE THERAPEUTIC 

POTENTIAL OF TOLL-LIKE RECEPTORS

Symposium

(Sponsored by: The Divisions for Cardiovascular 

Pharmacology & Integrative Systems, Translational and 

Clinical Pharmacology)

s

un

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 108

C

haired

: C. W

eBB

 

anD

 s. G

oulopoulou

3:00 

Danger, tissue injury and immunity. 

P. Matzinger. NIAID, 

NIH.

3:25 

Toll-like receptors in gestational hypertension. 

B. Mitchell. 

Texas A&M Hlth. Sci. Ctr.

3:50 

Innate immune mechanisms in viral myocarditis. 

J. 

Vallejo. Baylor Col. of Med.

4:15 

Toll-like receptors: therapeutic targets in cardiovascular 

disease? 

C. Monaco. Univ. of Oxford.

4:40 

The influence of methadone on Toll-like receptor 4 and 

human mu opioid receptor expression. 

S. Dodson, S. 

Das, R. Davis and C.W. Stevens. Oklahoma State 

Univ. Ctr. for Hlth. Sci. 

(1175.9)

4:55  Chronic Toll-like receptor 9 activation mediates 

heightened vascular contractility via attenuated NOS 

activity in isolated aortic segments. 

C. McCarthy, S. 

Goulopoulou, C. Wenceslau, T. Matsumoto and 

R.C. Webb. Georgia Hlth. Sci. Univ. and Hoshi Univ., 

Japan. 

(878.6)

5:10  Testosterone induces activation of the extrinsic 

apoptotic pathway in VSMC by mechanisms involving 

ROS generation. 

R. Lopes, K. Neves, A. Chignalia, 

C. Zanotto, C. Pestana, C. Curti and R. Tostes. Univ. 

of São Paulo, Ribeirão Preto. 

(1092.8)

151.  THERAPEUTIC APPROACHES FOR ERECTILE 

DYSFUNCTION (ED) AND BENIGN PROSTATIC 

HYPERPLASIA (BPH): PRESENT AND FUTURE

Symposium

(Sponsored by: The British Pharmacological Society; and 

the ASPET Divisions for Cardiovascular Pharmacology; 

Drug Discovery and Development; and Integrative 

Systems, Translational and Clinical Pharmacology)

s

un

. 3:00 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 109a

C

haired

: s. C

elleK

3:00 

Pathophysiological link between ED and BPH. 

S. Cellek. 

Cranfield Univ., U.K.

3:30 

Soluble guanylate cyclase activators for ED. 

P. Sandner. 

Bayer HealthCare AG, Wuppertal.

4:00 

PDE5 inhibitors for treatment of BPH. 

A. Burnett. Johns 

Hopkins Hosp.

4:30 

Novel therapeutic approaches to ED and BPH. 

M. 

O’Leary. Harvard Med. Sch.

5:00 

Use of PDE5 inhibitors in indications other than ED and 

BPH. 

I. Eardley. Leeds Royal Infirmary.

SUNDAY PHARMACOLOGY

44

Physiology

154.  EMERGING CONCEPTS IN AMPK FUNCTION

Symposium

s

un

. 8:00 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 210a

C

haired

: J. C

reiGhton

 

anD

 J. z

miJeWsKi

8:00 

AMPK: the energy sensor that regulates all aspects of 

cell function. 

G. Hardie. Univ. of Dundee.

8:30 

AMPK and the inflammatory response. 

G. R. Steinberg. 

McMaster Univ., Canada.

9:00  Physiological outcomes of AMPK signaling 

compartments. 

R. Shaw. Salk Inst. for Biol. Sci.

9:30 

AMPK, inflammation, and the cardiovascular system. 

K. 

Walsh. Boston Univ. Sch. of Med.

155.  LABORATORY EXERCISES, CASE 

STUDIES AND MODELS FOR TEACHING 

PHYSIOLOGICAL CONCEPTS

Featured Topic

(Sponsored by: APS Teaching of Physiology Section)

s

un

. 8:00 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 207

C

haired

: n. l

orr

Education

8:00 Introduction. 

N. Lorr. Cornell Univ.

8:10 

A pretty model in itself more engaging and inspiring 

than copious content extracted from our minds! 

S. E. 

DiCarlo. Wayne State Univ.

8:30 

A hands on model of skeletal muscle reflexes, tone and 

innervation. 

J. Nielson and H. Carvalho. Virginia 

Tech Carillon Sch. of Med., Roanoke. 

(517.14)

8:45 

Using simulated diving to teach undergraduate science 

students integrative physiology. 

J. Choate, R. Evans, 

K. Denton and Y. Hodgson. Monash Univ., Australia. 

(517.13)

9:00 

Development of a manipulative for renal physiology 

teaching. 

Z. Giffen and H. Carvalho. Virginia Tech 

Carilion Sch. of Med., Roanoke. 

(517.20)

9:15 

Using student-created case studies to teach respiratory 

physiology. 

K. Hull. Bishop’s Univ., Canada. (517.11)

9:30 

Systems approach to digestive and regulatory processes 

through exploration of fasting and postprandial blood 

glucose levels. 

M.K. Hopper. Univ. of Southern 

Indiana. 

(517.10)

9:45 

Teaching circulatory responses to exercise using a 

classic paper by Grimby et al. 

H. Tanaka. Univ. of 

Texas at Austin. 

(517.9)

152.  ANIMAL MODELS OF THE IRRITABLE BOWEL 

SYNDROME: BASIC AND TRANSLATIONAL 

IMPLICATIONS

Symposium

s

un

. 3:15 

pm

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 210BC

C

haired

: J. J. G

allliGan

Translational Physiology

3:15 

The challenging irritable bowel syndrome patient. 

B. 

Kuo. Massachusetts Gen. Hosp., Harvard Med. Sch.

3:45 

Inflammation and the irritable bowel syndrome, lessons 

from animal models. 

G. Mawe. Univ. of Vermont.

4:15 

Early life adversity and lifelong visceral pain. 

A. 

Chaloner. Univ. of Oklahoma Hlth. Sci. Ctr.

4:45 

Animal models of IBS: strengths and weaknesses for 

drug development. 

S. Bradesi. UCLA.

153.  EMERGING CONCEPT: CENTRAL 

MECHANISMS INVOLVING BRAIN RENIN-

ANGIOTENSIN SYSTEMS AND INFLAMMATION 

IN HYPERTENSION AND CARDIOVASCULAR 

DISEASE

Symposium

(Sponsored by: APS Neural Control and Autonomic 

Regulation)

s

un

. 8:00 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 206B

C

haired

: m. K. r

aizaDa

 

anD

 y. F

enG

Blood Pressure Regulation

Inflammation and Immune Responses

8:00  Autonomic neural regulation of immune system: 

implications for hypertension. 

F. M. Abboud. Univ. of 

Iowa.

8:30 

Role of microglia in regulation of vascular reparative and 

inflammatory cells in hypertension. 

M. K. Raizada. 

Univ. of Florida.

9:00 

The brain in heart failure: what’s inflammation got to do 

with it? 

R. B. Felder. Univ. of Iowa.

9:30 

Renin angiotensin system in multiple sclerosis: new 

targeted therapy. 

L. Steinman. Stanford Univ.

APS President’s Symposium Series

From Animals to Human Models of Disease

PHYSIOLOGY SUNDAY

45

S

U

N

156.  LYMPH COLLECTORS AS ACTIVE PLAYERS: 

IMMUNITY, NUTRIENTS, FLUID FLOW

Symposium

(Sponsored by: APS Cardiovascular Section)

s

un

. 8:00 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 211

C

haired

: a. a. G

ashev

 

anD

 l. s

antamBroGio

Inflammation and Immune Responses

Translational Physiology

8:00 

Why is the lymph fistula rat excellent for studying incretin 

secretion by the gut? 

P. Tso. Univ. of Cincinnati.

8:30 

Biological significance of self-antigens present in the 

human lymph. 

L. Santambrogio. Albert Einstein Col. 

of Med.

9:00 

Bi-directional interactions between adult and aged 

mesenteric lymph collectors and adjacent mast cells. 

A. Gashev. Texas A&M Hlth. Sci. Ctr. Col. of Med.

9:30 

Unique interactions between antigen presenting cells 

and the lymphatics. 

D. Zawieja. Texas A&M Hlth. Sci. 

Ctr. Col. of Med.

157.  NEW EXPERIMENTAL APPROACHES TO 

HUMAN BRAIN FUNCTION IN HEALTH AND 

DISEASE

Symposium

(Sponsored by: The Society for Experimental Biology and 

Medicine)

s

un

. 8:00 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 208

C

haired

: m. J. F

rieDlanDer

Translational Physiology

8:00 

Positron emission tomography: a tool to explore 

pathophysiology and to facilitate therapeutic drug 

development. 

R. B. Innis. NIMH, NIH.

8:30 

Sub-second measurements of dopamine in human 

brain and their correlation with decision variables. 

P. 

R. Montague. Virginia Tech Carilion Res. Inst.

9:00 

Epistatic interactions of AKT1 on human medial temporal 

lobe biology and pharmacogenetic implications. 

D. R. 

Weinberger. Johns Hopkins Univ.

9:30 

Genomic duplication predisposes to disease risk and 

mediates gene innovations during human evolution. 

E. E. Eichler. HHMI, Univ. of Washington.

158.  NRF2 SIGNAL PATHWAY IN HUMAN DISEASES 

AS NOVEL THERAPEUTICS

Symposium

(Sponsored by: APS Physiologists in Industry Group)

s

un

. 8:00 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 205C

C

haired

: e. W. s

heK

 

anD

 i. J. s

mith

Translational Physiology

8:00 

The Nrf2-Keap1-ARE pathway and the dual role of Nrf2 

in cancer. 

D. Zhang. Univ. of Arizona Col. of Pharm.

8:30 

Nrf2 as a therapeutic target for COPD and other 

lung diseases. 

S. S. Biswal. Johns Hopkins Univ. 

Bloomberg Sch. of Publ. Hlth.

9:00 

Fetal programming of impaired Nrf2 mediated redox 

signaling in fetal endothelial cells. 

G. E. Mann. King’s 

Col. London Sch. of Med.

9:30 

Nrf2 signaling in the heart: mechanisms to therapeutics 

for cardiac diseases. 

N. S. Rajasekaran. Univ. of Utah 

Sch. of Med.

159.  PHYSIOLOGICAL GENOMIC APPROACHES IN 

HYPERTENSION RESEARCH

Symposium

(Sponsored by: APS Physiological Genomics Group)

s

un

. 8:00 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 209

C

haired

: D. l. m

attson

Blood Pressure Regulation

8:00 

RNA interference in hypertension. 

Z. Sun. Univ. of 

Oklahoma Hlth. Sci. Ctr.

8:30 

From GWAS to function for human disease through zinc 

finger nuclease gene disruption in the rat. 

C. Moreno-

Quinn. Med. Col. of Wisconsin.

9:00 

Renal medullary stem cell niche in salt-sensitive 

hypertension. 

N. Li. Virginia Commonwealth Univ.

9:30 

Regulatory RNAs as biomarkers of hypertension. 

B. 

Joe. Univ. of Toledo Col. of Med.

160.  PLATELET-IMMUNE CELL INTERACTIONS IN 

CARDIOVASCULAR DISEASES

Symposium

(Sponsored by: APS Cardiovascular Section)

s

un

. 8:00 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 206a

C

haired

: r. r

umBaut

 

anD

 D. n. G

ranGer

Inflammation and Immune Responses

Translational Physiology

8:00 

Platelets as modulators of the innate immune response. 

J. W. Semple. Li Ka Shing Knowledge Inst., St. 

Michael’s Hosp., Toronto.

8:30 

Platelet-immune cell interactions in atherosclerosis. 

K. 

Ley. La Jolla Inst. for Allergy and Immunol.

9:00 

Roles of platelet- and monocytic-microparticles in 

hemostasis and thrombosis. 

N. Mackman. Univ. of 

North Carolina at Chapel Hill Sch. of Med.

9:30 

Platelet-neutrophil interdependence in microvascular 

inflammation. 

R. Rumbaut. Michael E. DeBakey VA 

Med. Ctr., Houston.

SUNDAY PHYSIOLOGY

46

161.  TARGETING HYPOXIC PATHWAYS FOR 

THERAPEUTIC BENEFIT

Symposium

(Sponsored by: APS Hypoxia Group)

s

un

. 8:00 

am

—B

oston

 C

onvention

 & e

xhiBition

 C

enter

, 205B

C

haired

: C. t. t

aylor

Hypoxia and Oxidative Stress

8:00 

Targeting HIF-dependent pathways in disease. 

G. 

Semenza. Johns Hopkins Univ. Sch. of Med.

8:30 

Targeting hypoxia inducible pathways in the GI tract. 

S. 

Colgan. Univ. of Colorado Denver.

9:00 

Targeting HIF hydroxylases for therapeutic benefit.